Search results
Results From The WOW.Com Content Network
Caesium in the body has a biological half-life of about one to four months. Mercury (as methylmercury) in the body has a half-life of about 65 days. Lead in the blood has a half life of 28–36 days. [29] [30] Lead in bone has a biological half-life of about ten years. Cadmium in bone has a biological half-life of about 30 years.
The drug is highly cardioselective at 5 mg. [19] In addition, at doses above 10 mg, nebivolol loses its cardioselectivity and blocks both β1 and β2 receptors, [18] while the recommended starting dose of nebivolol is 5 mg, sufficient control of blood pressure may require doses up to 40 mg. [18] Furthermore, nebivolol is also not ...
A drug's characteristics make a clear distinction between tissues with high and low blood flow. Enzymatic saturation: When the dose of a drug whose elimination depends on biotransformation is increased above a certain threshold the enzymes responsible for its metabolism become saturated. The drug's plasma concentration will then increase ...
Alternatively, since the radioactive decay contributes to the "physical (i.e. radioactive)" half-life, while the metabolic elimination processes determines the "biological" half-life of the radionuclide, the two act as parallel paths for elimination of the radioactivity, the effective half-life could also be represented by the formula: [1] [2]
Radioactive isotope table "lists ALL radioactive nuclei with a half-life greater than 1000 years", incorporated in the list above. The NUBASE2020 evaluation of nuclear physics properties F.G. Kondev et al. 2021 Chinese Phys. C 45 030001. The PDF of this article lists the half-lives of all known radioactives nuclides.
The absorption rate constant K a is a value used in pharmacokinetics to describe the rate at which a drug enters into the system. It is expressed in units of time −1. [1] The K a is related to the absorption half-life (t 1/2a) per the following equation: K a = ln(2) / t 1/2a. [1] K a values can typically only be found in research articles. [2]
Prazosin is active after taken by mouth and has a minimal effect on cardiac function due to its α 1-adrenergic receptor selectivity.When prazosin is started, however, heart rate and contractility can increase in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure.
Labetalol was the first drug created that combined both α- and β-adrenergic receptor blocking properties. It was created to potentially fix the compensatory reflex issue that occurred when blocking a single receptor subtype, i.e. vasoconstriction after blocking β-adrenergic receptors or tachycardia after blocking α-adrenergic receptors.